BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17024793)

  • 1. In vitro induction of resistance by tissue concentrations of azithromycin, clarithromycin, cefixime and amoxicillin/clavulanate in clinical isolates of Streptococcus pyogenes.
    De Vecchi E; Nicola L; Zucchetti E; Drago L
    J Chemother; 2006 Aug; 18(4):379-88. PubMed ID: 17024793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro selection of resistance to clarithromycin in Streptococcus pneumoniae clinical isolates.
    Drago L; De Vecchi E; Nicola L; Legnani D; Prenna M; Ripa S
    J Chemother; 2005 Apr; 17(2):161-8. PubMed ID: 15920900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
    Berry V; Thorburn CE; Knott SJ; Woodnutt G
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3193-9. PubMed ID: 9835514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin.
    Clark C; Bozdogan B; Peric M; Dewasse B; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2956-62. PubMed ID: 12183253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro.
    Van Asselt GJ; Sloos JH; Mouton RP; Van Boven CP; Van de Klundert JA
    J Med Microbiol; 1995 Nov; 43(5):386-91. PubMed ID: 7563004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial susceptibility and macrolide resistance genes in Streptococcus pyogenes collected in Austria and Hungary.
    Gattringer R; Sauermann R; Lagler H; Stich K; Buxbaum A; Graninger W; Georgopoulos A
    Int J Antimicrob Agents; 2004 Sep; 24(3):290-3. PubMed ID: 15325435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Macrolide antibiotic resistance rates and phenotypes of group A beta hemolytic streptococci isolated between the years 1999-2000 and 2001-2002].
    Senses Z; Baysallar M; Gür D; Doğanci L
    Mikrobiyol Bul; 2003 Oct; 37(4):225-34. PubMed ID: 14748258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of ceftibuten, cefaclor, azithromycin, clarithromycin, erythromycin and telithromycin against Streptococcus pyogenes clinical isolates with different genotypes and phenotypes.
    Drago L; Ripa S; Zampaloni C; De Vecchi E; Vitali LA; Petrelli D; Prenna M
    Chemotherapy; 2005 Aug; 51(5):268-71. PubMed ID: 16088124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus.
    Maurer FP; Castelberg C; Quiblier C; Böttger EC; Somoskövi A
    J Antimicrob Chemother; 2014 Jun; 69(6):1559-63. PubMed ID: 24500188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study.
    Malhotra-Kumar S; Lammens C; Coenen S; Van Herck K; Goossens H
    Lancet; 2007 Feb; 369(9560):482-90. PubMed ID: 17292768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of antimicrobial susceptibility of clinical isolates of Streptococcus pyogenes in Japan: report of a countrywide surveillance study.
    Hotomi M; Billal DS; Shimada J; Yamauchi K; Fujihara K; Yamanaka N;
    J Infect Chemother; 2005 Feb; 11(1):48-51. PubMed ID: 15729489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Streptococcus pneumoniae in vitro development of resistance to amoxicillin/clavulanic acid, cefaclor, levofloxacin and azithromycin.
    Koeth LM; Good CE; Saunders KA; Jakielaszek C
    Int J Antimicrob Agents; 2004 Aug; 24(2):144-9. PubMed ID: 15288313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The differential effect of clarithromycin and azithromycin on induction of macrolide resistance in
    Schildkraut JA; Pennings LJ; Ruth MM; de Brouwer AP; Wertheim HF; Hoefsloot W; de Jong A; van Ingen J
    Future Microbiol; 2019 Jun; 14():749-755. PubMed ID: 31271060
    [No Abstract]   [Full Text] [Related]  

  • 15. Enhancement of antimicrobial activities of cefteram or clavulanic acid/amoxicillin against cefixime-resistant Neisseria gonorrhoeae in the presence of clarithromycin or azithromycin.
    Onodera S; Kiyota H; Endo K; Suzuki H; Hosobe T; Takahashi T; Egawa S; Kobayashi I
    J Infect Chemother; 2006 Aug; 12(4):207-9. PubMed ID: 16944260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial resistance of Staphylococcus aureus and oral streptococci strains from high-risk endocarditis patients.
    Groppo FC; Castro FM; Pacheco AB; Motta RH; Filho TR; Ramacciato JC; Florio FM; Meechan JG
    Gen Dent; 2005; 53(6):410-3. PubMed ID: 16366048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High macrolide resistance in Streptococcus pyogenes strains isolated from children with pharyngitis in China.
    Liu X; Shen X; Chang H; Huang G; Fu Z; Zheng Y; Wang L; Li C; Liu L; Shen Y; Yang Y
    Pediatr Pulmonol; 2009 May; 44(5):436-41. PubMed ID: 19360846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative in vitro activity of new oral macrolides against Streptococcus pyogenes strains].
    Prado V; Romero J; Herrera N; Marinkovic K; Bustos R
    Rev Med Chil; 1993 Oct; 121(10):1128-34. PubMed ID: 8191116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alarming trend of clarithromycin-resistant Streptococcus pyogenes in Japan (1998-2002).
    Kobayashi I; Hasegawa M; Kanayama A; Saika T; Shimada J
    J Infect Chemother; 2005 Apr; 11(2):56-8. PubMed ID: 15856371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes.
    Amábile-Cuevas CF; Hermida-Escobedo C; Vivar R
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S30-2. PubMed ID: 11249826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.